Curi Bio, a Seattle-based company working to improve R&D decision making for biopharma companies, raised $10 million in a Series B funding round led by DreamCIS. The company aims to reduce clinical trial failure rates and the time and cost of bringing new therapeutics to market.
Curi Bio provides human-relevant functional data to help guide decisions in drug development and manufacturing. Its platform strategy combines human iPSC-derived cells; biosystems that mature those cells and measure complex functional data; and analysis that highlights functional phenotypic insights to improve predictive screening.
“This investment enables us to aggressively scale our integrated platforms, providing our biopharma partners with predictive, functional data on human systems across a variety of devastating diseases like muscle metabolism and wasting, neuromuscular diseases like ALS, cardiac indications, and beyond,” Nicholas Geisse, Curi Bio’s CEO, said in a statement. “The data we deliver to our clients through our products and services ultimately de-risks their R&D pipelines and accelerates the development of safer, more effective medicines for patients.”
